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Abstract The Fab fragment of a rat monoclonal antibody (no. 
192) with very high affhrity for the main immunogenic region of 
the human muscle nicotinic acetylcholine receptor (AChR) has 
been purified, characterised and crystallised using vapour 
diffusion techniques. Its Kd for human AChR was determined 
to be 5X 10-r’ M. Its cross-reactivity pattern suggests that 
residue a23 of the AChR strongly affects its epitope. Crystals 
suitable for X-ray analysis, obtained by micro- and macroseeding 
techniques, belong to the orthorhombic space group C2221 and 
they diffract to 2.8 A resolution usOing synchroqon radiation. The 
unit cell dimensions are a = 83.4 A, b = 110.0 A and c = 212.2 A 
and there are two Fab molecules per asymmetric unit. 
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1. Introduction 
The nicotinic acetylcholine receptor (AChR) of mammalian 
m#iscle is a ligand-gated cation channel, composed of five 
hc mologous subunits in a stoichiometry c&S or aa@6 [I]. 
A(lhR appears to be the target of an antibody-mediated auto- 
immune response, which causes the disorder myasthenia 
gr.lvis (MG). Anti-AChR autoantibodies cause AChR loss 
and blockage of the function of AChR molecules, resulting 
in failure of the neuromuscular transmission [2]. 
The majority of the anti-AChR antibodies in sera of MG 
patients compete for binding to a region in the extracellular 
suJ.face of the a-subunit of the AChR, called the main immu- 
nogenic region (MIR) [3,4]. Anti-MIR monoclonal antibodies 
(n:Abs) induce experimental MG when injected into rats [4,5] 
and when added to cell cultures cause AChR loss via antigenic 
modulation [6,7]. Contrary to the intact antibodies, their Fab 
frz gments, being univalent, do not crosslink the AChR mole- 
cules, and thus they do not cause antigenic modulation. In 
fat t it has been shown, in muscle cell cultures, that these Fabs 
ar : capable of efficiently protecting the AChR against loss 
induced by human MG patients’ sera [6,7], suggesting that 
th’:y may be therapeutically useful. 
Anti-MIR mAb binding has been localised between amino 
acid residues 67 and 76 of the cc-subunit of Torpedo and hu- 
rn;n AChR [S]. Peptide analogue studies revealed the anti- 
genie role of each residue within 67-76; the segment 67-71 
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proved the most critical and sufficient for mAb binding [9]. 
The approximate location of the MIR on the intact AChR 
has been recently determined by electron microscopy to be at 
the extreme synaptic end of the a-subunit of the AChR [lo]. 
Despite thorough investigation of the MIR, little is known 
about the characteristics of the anti-MIR antibodies. The de- 
tailed knowledge of the structure of anti-MIR Fabs is essen- 
tial in order to understand the molecular details of the inter- 
action between the AChR and anti-MIR antibodies. Based on 
this knowledge we will be able to construct high affinity hu- 
manised mutants of antibody fragments for use as efficient 
protectors of the AChR against the pathogenic activity of 
anti-AChR antibodies, in trials for MG treatment. 
In this report we present results concerning the anti-MIR 
Fab 192. The Fab fragment was extensively purified and its 
affinity for the human muscle AChR was determined. Subse- 
quently the Fab was crystallised and X-ray diffraction data 
were obtained at 2.8 A resolution, which is currently used for 
structure determination. 
2. Materials and methods 
2.1. Protein purification 
The anti-MIR mAb 192 is an IgG2b antibody derived from the 
fusion of the spleen cells of a Lewis rat immunised by intact human 
muscle AChR, with the non-secreting mouse myeloma cell line S194/ 
5.XXO.BD.l. The mAb preparation was obtained from hybridoma 
serum-free supernatants, concentrated 100 times by Amicon ultrafil- 
tration and dialysed against phosphate-buffered saline (PBS, pH 7.4). 
The concentrate was applied on a 20 ml diethylaminoethyl (DEAE)- 
Sepharose Fast Flow (Pharmacia), equilibrated with Tris-HC1 20 mM, 
pH 8.0, and eluted using a continuous salt gradient, &l M NaCl, in 
the same buffer. The purified mAb was treated for 1 h with mercuri- 
papain (Sigma) at 37°C at an enzyme/substrate ratio of 1 :lOO in 150 
mM sodium-phosphate buffer, pH 7.0, containing 2 mM EDTA and 
10 mM L-cysteine. The reaction was halted by the addition of iodo- 
acetamide to a final concentration of 25 mM. 
The Fab was separated from the Fc and traces of remaining intact 
IgG by running the digest at pH 9.5 (20 mM ethanolamine-HCl) 
through a 40 ml Q-Sepharose Fast Flow anion exchange column 
(Pharmacia), using a linear salt gradient 0.0-0.5 M NaCI. The Fab 
fractions were further purified using a chromatofocusing column 
(Polybuffer Exchanger 94, Pharmacia) equilibrated with 25 mM etha- 
nolamine pH 9.4 by running a shallow pH gradient 9.0-8.0 using 
Polybuffer 96-HCI pH 8.0. Finally, the purified Fab was loaded on 
a gel filtration column (Sephacryl S-200 HR, Pharmacia) to remove 
the Polybuffer. For all chromatographic steps an FPLC system (Phar- 
macia) was used. 
2.2. AChRs. radioimmunoassays and afinity determination 
Extracts of cell culture of the human rhabdomyosarcoma cell line 
TE671 were used as human muscle AChR source. Rat and mouse 
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skeletal muscle extracts were used as sources of rat and mouse AChR, 
respectively. Binding of the intact mAb 192 and its proteolytic Fab 
fragments, as well as of the intact anti-MIR mAbs 198 and 35, to 
AChRs from various sources was tested by radioimmunoassay using 
[‘251]a-bungarotoxin-labelled AChR [l 11. Their binding affinities were 
calculated by Scatchard plots [12]. 
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2.3. Crystalhation and X-ray data collection 
The purified Fab solution was concentrated to 5-15 mg/ml using 
Amicon Centricon 10 microconcentrator. Protein concentration was 
determined by the Bradford Coomassie blue protein assay [13]. Crys- 
tallisations were carried out using the sitting and hanging drop tech- 
niques at 4”C, 16°C and room temperature (20-23°C). 2-5 ~1 of the 
protein solution was mixed with an equal volume of reservoir solution 
containing l&30% w/v PEG 6000 (Hampton) and O-300 mM NaCl. 
All reservoir solutions contained 2mM EDTA and 0.02% (w/v) so- 
dium azide. The pH was screened over a range from 6.0 to 9.5 and the 
concentration of the protein, PEG 6000 and NaCl was optimised. 
Also, the influence of various salts on the crystallisation was examined 
(LiCl, (NH&Sod, CaClz, Li2S04, MgC12, HCOONa) at concentra- 
tions of 0.1-0.5 M, but the best crystals were obtained with NaCl. 
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Diffraction data were recorded from Fab crystals on stations PX 
9.5 and 9.6 of the Synchrotron Radiation Source (SRS-CLRC) at 
Daresbury Laboratory, UK, using a 30 cm diameter MAR Research 
image plate, and on the EMBL Synchrotron beamline X 11 at DESY, 
Hamburg. Raw data images were indexed, integrated and corrected 
for Lorentz and polarisation effects using the program DENZO [14]. 
All data were scaled and merged using the program SCALEPACK 
v41. 
Fig. 1. Schematic presentation of the elution of the various isoforms 
of Fab 192 on a Polybuffer Exchanger 94 (PBE 94, Pharmacia) col- 
umn. The column (70 ml) was equilibrated with 25 mM ethanol- 
amine-HCl, pH 9.4 and eluted with Polybuffer 96-HCl, pH 8.0. A 
linear pH gradient 9.0-8.0 was formed. Fractions (5 ml) were col- 
lected at a flow rate of 1.2 ml/min. All peaks contain Fab fragments 
of different p1. 
3. Results and discussion 
tested for binding to the [1251]cl-bungarotoxin-labelled AChR. 
Fractions of the first and second peak in Fig. 1 were found to 
bind equally well to AChR, whereas the protein of the third 
peak had a much lower affinity for AChR. 
3.1. PuriJication 
Under the conditions described in Section 2 for the Q-Se- 
pharose fractionation of the mAb proteolysate, the Fab frag- 
ments eluted as two adjacent peaks in the flow through and 
very early in the gradient whereas the intact IgG and the Fc 
fragment eluted at much higher salt concentrations. The frac- 
tions containing the Fab fragment were initially analysed by 
both reducing and non-reducing sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis (SDS-PAGE). Under non- 
reducing SDS-PAGE, all Fab aliquots migrated as a single 
band at approximately 50 kDa whereas under reducing con- 
ditions they appeared as two adjacent bands at 25 kDa. 
3.2. Afinity determination 
Table 1 summarises the binding affinities of mAb and Fab 
192 for AChRs from various species and compares them with 
those of two extensively studied pathogenic anti-MIR mAbs 
(nos. 35 and 198). It is apparent that the mAb 192 affinity for 
the human muscle AChR is about lOO-fold higher than the 
corresponding affinity of mAbs 35 and 198. 
However, when the same fractions were analysed by analy- 
tical isoelectric focusing (IEF) using agarose gel (Pharmacia), 
each of the two Fab containing peaks was analysed into sev- 
eral bands. This heterogeneity in p1 is observed in several 
cases of Fabs [15,16] and is known to prevent the growth of 
diffraction quality crystals. Therefore, further purification 
with the chromatofocusing column was an essential step. 
Fig. 1 illustrates the chromatofocusing analysis of the first 
eluted peak from the Q-Sepharose column, into three major 
peaks. Analytical IEF gels of these peaks showed almost com- 
plete separation of the isoforms (Fig. 2). All fractions were 
The highly reduced binding affinity of mAb 192 for rat, but 
not for mouse AChR is surprising. Use of AChR hybrids has 
shown that the epitope for mAb 192 on human c1 subunit is 
not affected when the human p, y and 6 subunits are substi- 
tuted by the, quite different, Torpedo p, y and 6 subunits 
(Loutrari and Tzartos, unpublished observations). Therefore, 
the reduced affinity of mAb192 for rat AChR should be due 
to differences within the c1 subunit and not to conformational 
constraints imposed by the other rat subunits. There are only 
two residues in the extracellular parts of the AChR CL subunit 
(residues ~~-209, 268-292 and 428437) in which the rat ~1 
subunit differs from both the human and mouse a subunits 
[17,18]. These are residues 23 (Glu -+ Gly) and 195 (Asp, 
Thr+Asn). a195 is next to Cys192-Cys193 that are involved 
in the acetylcholine binding, which is remote from the MIR 
Table 1 
Affinities (Kd in nM) of anti-MIR antibodies for intact AChRs from various sourcesa 
Anti-MIR antibody AChR from: 
Human muscle Rat muscle Mouse muscle Torpedo electric organ 
mAb 192 0.01 646 0.04 m 
Fab 192 0.05 N.T. N.T 00 
mAbl98 21.6 7.4 16.4 1.8 
mAb35 >20 42 37 0.6 
“The &s were calculated by Scatchard plots using the results of radioimmunoassays with [ 1251]a-bungarotoxin-labelled AChRs from cell culture or 
muscle extracts. 
N.T.: not tested. 
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on the intact AChR [lo]. Therefore, we conclude that, on the 
inract AChR, a23 may be located near the MIR segment 
a67-76, or that elimination of the negative charge of ~123 
strongly affects the MIR epitope for mAb 192. 
3. f, Crystallisation 
The initial crystallisation trials of the protein which was 
el; tted in the second peak in Fig. 1 yielded crystals from drops 
cc ntaining equal volumes of aqueous protein solution (12 mg/ 
m ) and a reservoir solution containing 18% w/v PEG 6000 
ai d 150 mM NaCl, buffered with 100 mM bis-Tris-HCI pH 
7. i at 16°C. Under these conditions crystals were obtained 
01 ly by the high affinity Fab isoforms eluted from the PBE 
cc lumn (first and second peak in Fig. 1). Nevertheless these 
cr rstals were small to medium size rods, all of poor morphol- 
o&y and often badly twinned or fused together. Therefore, 
m cro- and macroseeding techniques [19] were employed in 
01 Jer to obtain larger, single crystals. One of the initial crystal 
cl lsters was crushed in 100 pl of stabilising solution (12% w/v 
Pl :G 6000), to produce a stock solution of microseeds. These 
m croseeds were diluted before being added to fresh drops. 
T! e medium size single rods which were grown from the mi- 
cr jseeded drops were transferred after a few days to fresh 
dr jps, in order to optimise their size. The macroseeded drops 
WI re equilibrated over a reservoir containing a lower concen- 
tr: tion of precipitant than the concentration which originally 
yb lded crystals. 
‘3btaining well ordered crystals of Fab 192, suitable for X- 
ra J diffraction analysis, was found to be critically dependent 
or an efficient (single band in IEF gel) and fast purification, 
pe -formed just before crystallisation. 
3.. X-ray crystallographic analysis 
Two data sets were collected (3.2 and 2.8 A) to form the 
co nplete data set which is currently used for structural ana- 
1y:is (Table 2). The crystals belong to orthorhombic space 
gr mp C222i with unit cell dimensions ~~~83.4 A, b=llO.O A 
an 1 c=212.2 A, with two Fab molecules per asymmetric unit 
an 149.9% of solvent in the crystal. The final data set is 90.4% 
co nplete to 4.0 A and 74.8% complete to 2.8 A, with an 
o\ :rall R-factor of 8.5%. Attempts to determine the structure 
by molecular replacement, using the programs AMoRe [20] 
an 1 X-PLOR [21] and existing Fab structures from the Pro- 
Ta )le 2 
X-’ ay data collection and processing statistics 
SRS set I SRS set II 
Re ,olution (A) 3.2 2.8 
Cr stal to detector distance 463 mm 465 mm 
Ex ,osure time pezr image 100 s 120 s 
W: velength (A) 1 .oo 0.87 
N~,mber of crystals 1 1 
0s illation range 1.5” 1.0” 
N,, 18395 26 126 
N 
0: :rall completeness 
11295 16 163 
67.8% 65.4% 
II0 r) 12.80 16.83 
R n. ‘ge (“/o) 6.7 7.0 
Outer shell (A) 3.3-3.2 2.9-2.8 
Co npleteness of the outer shell 45.05% 40.10% 
- 
N,, : number of measurements recorded; N, : number of unique reflec- 
tions; Rmerge: &(xj IZij- < Zi > I)Z&Zi, Z1,h is the scaled intensity of the 
jth observation of each unique reflection i and <I, > is the mean 
valsie. 
Fig. 2. Native isoelectric focusing agarose gel (pH 3.5510) of puri- 
fied Fab molecules eluted from the PBE 94 column. The gel was 
stained with Coomassie brilliant blue R-250, according to the manu- 
facturer’s (Pharmacia) protocol. Lane indications correspond to the 
eluted fraction numbers (the indication ‘total’ corresponds to the 
mAb proteolysate). 
tein Data Bank as search models, are in progress. The primary 
structure of the heavy and light variable domains of mAb 192 
has been recently determined by cloning and sequencing their 
cDNA (A. Mamalaki, P. Tsantili, C. Skarimba and S.J. Tzar- 
tos, unpublished data). 
The X-ray structure analysis of the Fab 192 should provide 
insight into the interaction with the human AChR of an anti- 
body that has all the characteristics of an efficient protecting 
agent of the myasthenic patients’ AChR: it binds at the MIR 
of the human AChR with an unusually high affinity for the 
receptor (the Kd value is 0.01 nM for the intact mAb and 0.05 
nM for the Fab), i.e. it is a unique candidate for future ther- 
apeutic applications in myasthenia gravis. 
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